{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:00:49Z","timestamp":1793073649813,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, there has been a substantial increase in the development of antitussive therapies and the first new\u00a0therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.<\/jats:p>","DOI":"10.1007\/s00408-023-00666-y","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T10:02:48Z","timestamp":1703152968000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Therapeutic Landscape in Chronic Cough"],"prefix":"10.1007","volume":"202","author":[{"given":"Jaclyn A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"5","key":"666_CR1","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1183\/09031936.00218714","volume":"45","author":"WJ Song","year":"2015","unstructured":"Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S et al (2015) The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J 45(5):1479\u201381","journal-title":"Eur Respir J"},{"issue":"3","key":"666_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chest.2017.05.038","volume":"152","author":"Y Colak","year":"2017","unstructured":"Colak Y, Nordestgaard BG, Laursen LC, Afzal S, Lange P, Dahl M (2017) Risk factors for chronic cough among 14,669 individuals from the general population. Chest 152(3):563\u201373","journal-title":"Chest"},{"key":"666_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019","author":"AH Morice","year":"2020","unstructured":"Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C et al (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01136-2019","journal-title":"Eur Respir J"},{"issue":"9","key":"666_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1513\/AnnalsATS.202302-174OC","volume":"20","author":"P Saunders","year":"2023","unstructured":"Saunders P, Wu Z, Fahy WA, Stewart ID, Saini G, Smith DJF et al (2023) The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study. Ann Am Thorac Soc 20(9):1267\u201373","journal-title":"Ann Am Thorac Soc"},{"key":"666_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1745-9974-6-4","volume":"6","author":"AL Key","year":"2010","unstructured":"Key AL, Holt K, Hamilton A, Smith JA, Earis JE (2010) Objective cough frequency in idiopathic pulmonary fibrosis. Cough 6:4","journal-title":"Cough"},{"key":"666_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01157-2017","author":"MJG van Manen","year":"2017","unstructured":"van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM et al (2017) Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01157-2017","journal-title":"Eur Respir J"},{"issue":"6","key":"666_CR7","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.chest.2019.12.038","volume":"157","author":"E Landt","year":"2020","unstructured":"Landt E, Colak Y, Lange P, Laursen LC, Nordestgaard BG, Dahl M (2020) Chronic cough in individuals with COPD: a population-based cohort study. Chest 157(6):1446\u201354","journal-title":"Chest"},{"key":"666_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106921","volume":"200","author":"R Hughes","year":"2022","unstructured":"Hughes R, Rapsomaniki E, Janson C, Keen C, Make BJ, Burgel PR et al (2022) Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and\/or COPD in the NOVELTY study. Respir Med 200:106921","journal-title":"Respir Med"},{"issue":"5","key":"666_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaci.2008.08.029","volume":"122","author":"PA Marsden","year":"2008","unstructured":"Marsden PA, Smith JA, Kelsall AA, Owen E, Naylor JR, Webster D et al (2008) A comparison of objective and subjective measures of cough in asthma. J Allergy Clin Immunol 122(5):903\u20137","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"666_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S et al (2016) Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47(2):410\u20139","journal-title":"Eur Respir J"},{"issue":"12","key":"666_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1164\/rccm.201508-1602OC","volume":"193","author":"MG Belvisi","year":"2016","unstructured":"Belvisi MG, Birrell MA, Khalid S, Wortley MA, Dockry R, Coote J et al (2016) Neurophenotypes in airway diseases. Insights from translational cough studies. Am J Respir Crit Care Med 193(12):1364\u201372","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"666_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1378\/chest.14-1481","volume":"146","author":"BJ Canning","year":"2014","unstructured":"Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L et al (2014) Anatomy and neurophysiology of cough: CHEST guideline and expert panel report. Chest 146(6):1633\u201348","journal-title":"Chest"},{"issue":"3","key":"666_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1164\/rccm.201912-2347OC","volume":"203","author":"CO Shapiro","year":"2021","unstructured":"Shapiro CO, Proskocil BJ, Oppegard LJ, Blum ED, Kappel NL, Chang CH et al (2021) Airway sensory nerve density is increased in chronic cough. Am J Respir Crit Care Med 203(3):348\u201355","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"666_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1164\/rccm.200612-1856OC","volume":"176","author":"SB Mazzone","year":"2007","unstructured":"Mazzone SB, McLennan L, McGovern AE, Egan GF, Farrell MJ (2007) Representation of capsaicin-evoked urge-to-cough in the human brain using functional magnetic resonance imaging. Am J Respir Crit Care Med 176(4):327\u201332","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"666_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/thoraxjnl-2015-207425","volume":"71","author":"A Ando","year":"2016","unstructured":"Ando A, Smallwood D, McMahon M, Irving L, Mazzone SB, Farrell MJ (2016) Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax 71(4):323\u20139","journal-title":"Thorax"},{"issue":"6","key":"666_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.rmed.2015.03.011","volume":"109","author":"E Hilton","year":"2015","unstructured":"Hilton E, Marsden P, Thurston A, Kennedy S, Decalmer S, Smith JA (2015) Clinical features of the urge-to-cough in patients with chronic cough. Respir Med 109(6):701\u20137","journal-title":"Respir Med"},{"issue":"11","key":"666_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/thx.2009.116723","volume":"64","author":"EC Young","year":"2009","unstructured":"Young EC, Brammer C, Owen E, Brown N, Lowe J, Johnson C et al (2009) The effect of mindfulness meditation on cough reflex sensitivity. Thorax 64(11):993\u20138","journal-title":"Thorax"},{"key":"666_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02203-2018","author":"PSP Cho","year":"2019","unstructured":"Cho PSP, Fletcher HV, Turner RD, Jolley CJ, Birring SS (2019) Impaired cough suppression in chronic refractory cough. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02203-2018","journal-title":"Eur Respir J"},{"key":"666_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01387-2020","author":"E Hilton","year":"2020","unstructured":"Hilton E, Satia I, Holt K, Woodcock AA, Belcher J, Smith JA (2020) The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01387-2020","journal-title":"Eur Respir J"},{"issue":"10328","key":"666_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J et al (2022) Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 399(10328):909\u201323","journal-title":"Lancet."},{"key":"666_CR21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04271-2020","author":"JA Smith","year":"2021","unstructured":"Smith JA, Holt K, Dockry R, Sen S, Sheppard K, Turner P et al (2021) Performance of a digital signal processing algorithm for the accurate quantification of cough frequency. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.04271-2020","journal-title":"Eur Respir J"},{"issue":"6","key":"666_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00408-022-00587-2","volume":"200","author":"J Schelfhout","year":"2022","unstructured":"Schelfhout J, Nguyen AM, Birring SS, Bacci ED, Vernon M, Muccino DR et al (2022) Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough. Lung. 200(6):717\u201324","journal-title":"Lung."},{"issue":"4","key":"666_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","volume":"58","author":"SS Birring","year":"2003","unstructured":"Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID (2003) Development of a symptom specific health status measure for patients with chronic cough: leicester cough questionnaire (LCQ). Thorax. 58(4):339\u201343","journal-title":"Thorax."},{"key":"666_CR24","doi-asserted-by":"publisher","first-page":"175346662210997","DOI":"10.1177\/17534666221099737","volume":"16","author":"AM Nguyen","year":"2022","unstructured":"Nguyen AM, Schelfhout J, Muccino D, Bacci ED, La Rosa C, Vernon M et al (2022) Leicester cough questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough. Ther Adv Respir Dis 16:17534666221099736","journal-title":"Ther Adv Respir Dis"},{"key":"666_CR25","doi-asserted-by":"publisher","first-page":"175346662110497","DOI":"10.1177\/17534666211049743","volume":"15","author":"A Martin Nguyen","year":"2021","unstructured":"Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D et al (2021) Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis 15:17534666211049744","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"666_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1378\/chest.15-1496","volume":"149","author":"P Gibson","year":"2016","unstructured":"Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS et al (2016) Treatment of unexplained chronic cough: chest guideline and expert panel report. Chest 149(1):27\u201344","journal-title":"Chest"},{"issue":"4","key":"666_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","volume":"175","author":"AH Morice","year":"2007","unstructured":"Morice AH, Menon MS, Mulrennan SA, Everett CF, Wright C, Jackson J et al (2007) Opiate therapy in chronic cough. Am J Respir Crit Care Med 175(4):312\u20135","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR28","first-page":"1159","volume":"60","author":"J King","year":"2022","unstructured":"King J, Wingfield-Digby J, Hennessey S, Smith JA, Marsden PM (2022) Real world effectiveness and tolerability of low-dose opiates for refractory\/unexplained chronic cough (RCC\/UCC) in a tertiary clinic [abstract]. Eur Respir J 60:1159","journal-title":"Eur Respir J"},{"key":"666_CR29","first-page":"A24","volume":"72","author":"B Al-Sheklly","year":"2017","unstructured":"Al-Sheklly B, Mitchell J, Issa B, Badri H, Satia I, Collier T et al (2017) Randomised control trial quantifying the efficacy of low dose morphine in a responder group of patients with refractory chronic cough [abstract]. Thorax 72:A24\u2013A2","journal-title":"Thorax"},{"issue":"1","key":"666_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13063-022-06068-4","volume":"23","author":"Z Wu","year":"2022","unstructured":"Wu Z, Banya W, Chaudhuri N, Jakupovic I, Maher TM, Patel B et al (2022) PAciFy cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary fibrosis cough. Trials 23(1):184","journal-title":"Trials"},{"key":"666_CR31","first-page":"OA4195","volume":"62","author":"Z Wu","year":"2023","unstructured":"Wu Z, Spencer LG, Banya W, Chaudhuri N, Rivera-Ortega P, Jakupovic I et al (2023) Morphine sulfate for the treatment of cough in Idiopathic pulmonary fibrosis the PAciFy cough randomized clinical trial [abstract]. Eur Respir J 62:OA4195","journal-title":"Eur Respir J"},{"issue":"5","key":"666_CR32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.amjmed.2005.10.046","volume":"119","author":"S Mintz","year":"2006","unstructured":"Mintz S, Lee JK (2006) Gabapentin in the treatment of intractable idiopathic chronic cough: case reports. Am J Med 119(5):e13-5","journal-title":"Am J Med"},{"issue":"1","key":"666_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1745-9974-8-9","volume":"8","author":"C Van de Kerkhove","year":"2012","unstructured":"Van de Kerkhove C, Goeminne PC, Van Bleyenbergh P, Dupont LJ (2012) A cohort description and analysis of the effect of gabapentin on idiopathic cough. Cough. 8(1):9","journal-title":"Cough."},{"issue":"9853","key":"666_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","volume":"380","author":"NM Ryan","year":"2012","unstructured":"Ryan NM, Birring SS, Gibson PG (2012) Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 380(9853):1583\u20139","journal-title":"Lancet"},{"issue":"12","key":"666_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/thx.2006.064337","volume":"61","author":"AE Vertigan","year":"2006","unstructured":"Vertigan AE, Theodoros DG, Gibson PG, Winkworth AL (2006) Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax 61(12):1065\u20139","journal-title":"Thorax"},{"issue":"2","key":"666_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/thoraxjnl-2016-208843","volume":"72","author":"SA Chamberlain Mitchell","year":"2017","unstructured":"Chamberlain Mitchell SA, Garrod R, Clark L, Douiri A, Parker SM, Ellis J et al (2017) Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax 72(2):129\u201336","journal-title":"Thorax"},{"issue":"12","key":"666_CR37","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1097\/01.mlg.0000244377.60334.e3","volume":"116","author":"A Jeyakumar","year":"2006","unstructured":"Jeyakumar A, Brickman TM, Haben M (2006) Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope 116(12):2108\u201312","journal-title":"Laryngoscope"},{"issue":"8","key":"666_CR38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/lary.27201","volume":"128","author":"CB Simpson","year":"2018","unstructured":"Simpson CB, Tibbetts KM, Loochtan MJ, Dominguez LM (2018) Treatment of chronic neurogenic cough with in-office superior laryngeal nerve block. Laryngoscope 128(8):1898\u2013903","journal-title":"Laryngoscope"},{"key":"666_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/lary.31061","author":"BA Quinton","year":"2023","unstructured":"Quinton BA, Tierney WS, Benninger MS, Nelson RC, Gau VL, Hrelec CM et al (2023) The role of bilateral superior laryngeal nerve block in managing refractory chronic cough. Laryngoscope. https:\/\/doi.org\/10.1002\/lary.31061","journal-title":"Laryngoscope"},{"issue":"10","key":"666_CR40","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/lary.30570","volume":"133","author":"N Talbot","year":"2023","unstructured":"Talbot N, Heller M, Nyirjesy S, Kim B, DeSilva B, Matrka L (2023) Superior laryngeal nerve block response rates in 54 neurogenic cough patients. Laryngoscope 133(10):2647\u201353","journal-title":"Laryngoscope"},{"key":"666_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/lary.31072","author":"BA Campbell","year":"2023","unstructured":"Campbell BA, Flormann VB, Davis RB, Mallur PS (2023) Efficacy of botulinum A injection to the laryngeal adductor compartment for treatment of cough. Laryngoscope. https:\/\/doi.org\/10.1002\/lary.31072","journal-title":"Laryngoscope"},{"issue":"9974","key":"666_CR42","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP et al (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385(9974):1198\u2013205","journal-title":"Lancet"},{"issue":"5","key":"666_CR43","doi-asserted-by":"publisher","first-page":"L858","DOI":"10.1152\/ajplung.90360.2008","volume":"295","author":"K Kwong","year":"2008","unstructured":"Kwong K, Kollarik M, Nassenstein C, Ru F, Undem BJ (2008) P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus. Am J Physiol Lung Cell Mol Physiol 295(5):L858-65","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"666_CR44","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.21099.1","author":"SC Kinnamon","year":"2019","unstructured":"Kinnamon SC, Finger TE (2019) Recent advances in taste transduction and signaling. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.21099.1","journal-title":"F1000Res"},{"key":"666_CR45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ et al (2020) Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01615-2019","journal-title":"Eur Respir J"},{"issue":"8","key":"666_CR46","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8(8):775\u201385","journal-title":"Lancet Respir Med"},{"issue":"2","key":"666_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","volume":"7","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Afzal AS, Smith JA, Ford AP, Li JJ, Li Y et al (2021) Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gefapixant, a P2X3 antagonist, in a randomized placebo-controlled clinical trial. Pulm Ther 7(2):471\u201386","journal-title":"Pulm Ther"},{"issue":"3","key":"666_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-022-00193-w","volume":"8","author":"JA Smith","year":"2022","unstructured":"Smith JA, Kitt MM, Bell A, Noulin N, Tzontcheva A, Seng MM et al (2022) Treatment with the P2X3-Receptor antagonist gefapixant for acute cough in induced viral upper respiratory tract infection: a phase 2a, randomized. Placebo-Controlled Trial. Pulm Ther 8(3):297\u2013310","journal-title":"Placebo-Controlled Trial. Pulm Ther"},{"key":"666_CR49","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04240-2020","author":"A Morice","year":"2021","unstructured":"Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A et al (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.04240-2020","journal-title":"Eur Respir J"},{"issue":"1","key":"666_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-023-02384-8","volume":"24","author":"C Friedrich","year":"2023","unstructured":"Friedrich C, Francke K, Birring SS, van den Berg JWK, Marsden PA, McGarvey L et al (2023) The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial. Respir Res 24(1):109","journal-title":"Respir Res"},{"issue":"3","key":"666_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","volume":"201","author":"PV Dicpinigaitis","year":"2023","unstructured":"Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L et al (2023) Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung 201(3):255\u201366","journal-title":"Lung"},{"key":"666_CR52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00725-2021","author":"A Niimi","year":"2022","unstructured":"Niimi A, Saito J, Kamei T, Shinkai M, Ishihara H, Machida M et al (2022) Randomised trial of the P2X(3) receptor antagonist sivopixant for refractory chronic cough. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00725-2021","journal-title":"Eur Respir J"},{"issue":"1","key":"666_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","volume":"201","author":"L McGarvey","year":"2023","unstructured":"McGarvey L, Smith JA, Morice A, Birring SS, Chung KF, Dicpinigaitis PV et al (2023) A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough. Lung. 201(1):25\u201335","journal-title":"Lung."},{"key":"666_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"D Garceau","year":"2019","unstructured":"Garceau D, Chauret N (2019) BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther 56:56\u201362","journal-title":"Pulm Pharmacol Ther"},{"key":"666_CR55","first-page":"A1019","volume":"203","author":"JA Smith","year":"2021","unstructured":"Smith JA, Morice A, Birring SS, Parker S, Marsden PA, Holcomb J et al (2021) Improvements in cough frequency over 24 hours with BLU-5937, a selective P2X3 antagonist, in patient subgroups defined by baseline awake cough frequencies [abstract]. Am J Respir Crit Care Med 203:A1019","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR56","first-page":"A2356","volume":"203","author":"C Bonuccelli","year":"2021","unstructured":"Bonuccelli C, Smith JA, Birring SS, Blaiss M, Dicpinigaitis P, Sher M et al (2021) Design of SOOTHE, a phase 2b dose finding study with BLU-5937, a selective P2X3 antagonist, in refractory chronic cough [abstract]. Am J Respir Crit Care Med 203:A2356","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR57","first-page":"810","volume":"60","author":"JA Smith","year":"2022","unstructured":"Smith JA, McGarvey L, Morice A, Birring SS, Hull JH, Lanouette S et al (2022) Improvements in awake cough frequency in SOOTHE, A phase 2b Trial of BLU-5937 in refractory chronic cough. Eur Respir J 60:810","journal-title":"Eur Respir J"},{"issue":"4","key":"666_CR58","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1378\/chest.12-1533","volume":"143","author":"KG Lim","year":"2013","unstructured":"Lim KG, Rank MA, Hahn PY, Keogh KA, Morgenthaler TI, Olson EJ (2013) Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series. Chest 143(4):1060\u20135","journal-title":"Chest"},{"issue":"4","key":"666_CR59","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jaip.2020.11.037","volume":"9","author":"R Abdulqawi","year":"2021","unstructured":"Abdulqawi R, Satia I, Kanemitsu Y, Khalid S, Holt K, Dockry R et al (2021) A randomized controlled trial to assess the effect of lidocaine administered via throat spray and nebulization in patients with refractory chronic cough. J Allergy Clin Immunol Pract 9(4):1640\u20137","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7162","key":"666_CR60","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nature06191","volume":"449","author":"AM Binshtok","year":"2007","unstructured":"Binshtok AM, Bean BP, Woolf CJ (2007) Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature 449(7162):607\u201310","journal-title":"Nature"},{"key":"666_CR61","first-page":"A2532","volume":"207","author":"JA Smith","year":"2023","unstructured":"Smith JA, Hull J, Birring S, Morice AH, Parker S, Marsden PA et al (2023) Randomized proof-of-concept study of AX-8, a TRPM8 agonist, inRefractory or unexplained chronic cough [abstract]. Am J Respir Crit Care Med 207:A2532","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR62","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300083","author":"TM Maher","year":"2023","unstructured":"Maher TM, Avram C, Bortey E, Hart N, Hirani N, Molyneux PL et al (2023) Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2300083","journal-title":"NEJM Evid"},{"issue":"6","key":"666_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1164\/rccm.202006-2359OC","volume":"203","author":"JA Smith","year":"2021","unstructured":"Smith JA, Harle A, Dockry R, Holt K, Russell P, Molassiotis A et al (2021) Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights. Am J Respir Crit Care Med 203(6):737\u201345","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR64","unstructured":"Efficacy and safety study of orvepitant for chronic cough in patients with idiopathic pulmonary fibrosis (IPF-COMFORT) 2023. https:\/\/clinicaltrials.gov\/study\/NCT05185089."},{"key":"666_CR65","unstructured":"A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough 2022. https:\/\/clinicaltrials.gov\/study\/NCT02993822."},{"issue":"1","key":"666_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaci.2014.01.038","volume":"134","author":"S Khalid","year":"2014","unstructured":"Khalid S, Murdoch R, Newlands A, Smart K, Kelsall A, Holt K et al (2014) Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol 134(1):56\u201362","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"666_CR67","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1164\/rccm.201704-0769OC","volume":"196","author":"MG Belvisi","year":"2017","unstructured":"Belvisi MG, Birrell MA, Wortley MA, Maher SA, Satia I, Badri H et al (2017) XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med 196(10):1255\u201363","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR68","first-page":"A6339","volume":"195","author":"JA Smith","year":"2017","unstructured":"Smith JA, Birrell MA, Wortley MA, Maher SA, Dockry R, Turner P et al (2017) TRPV1 antagonism with XEN-D0501 in chronic obstructive pulmonary disease: translation from pre-clinical model to clinical trial. Am J Respir Crit Care Med 195:A6339","journal-title":"Am J Respir Crit Care Med"},{"key":"666_CR69","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00269-2021","author":"VJ Ludbrook","year":"2021","unstructured":"Ludbrook VJ, Hanrott KE, Kreindler JL, Marks-Konczalik JE, Bird NP, Hewens DA et al (2021) Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00269-2021","journal-title":"ERJ Open Res"},{"issue":"1","key":"666_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jaci.2015.10.044","volume":"138","author":"SJ Bonvini","year":"2016","unstructured":"Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA et al (2016) Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: role of adenosine triphosphate. J Allergy Clin Immunol 138(1):249\u2013261","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"666_CR71","first-page":"712","volume":"55","author":"JA Smith","year":"2017","unstructured":"Smith JA, McGarvey LPA, Badri H, Satia I, Warren F, Siederer S et al (2017) Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough. Int J Clin Pharmacol Ther 55(9):712\u20139","journal-title":"Int J Clin Pharmacol Ther"},{"key":"666_CR72","doi-asserted-by":"publisher","first-page":"A52","DOI":"10.1136\/thoraxjnl-2015-207770.97","volume":"70","author":"I Satia","year":"2015","unstructured":"Satia I, Badri H, Dockry R, Chaudhuri N, Brown G, Abbott-Banner K et al (2015) A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with idiopathic pulmonary Fibrosis [abstract]. Thorax 70:A52","journal-title":"Thorax"},{"issue":"5","key":"666_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097005","volume":"9","author":"I Mukhopadhyay","year":"2014","unstructured":"Mukhopadhyay I, Kulkarni A, Aranake S, Karnik P, Shetty M, Thorat S et al (2014) Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One. 9(5):e97005","journal-title":"PLoS One."},{"issue":"9","key":"666_CR74","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1164\/rccm.202106-1485OC","volume":"205","author":"FJ Martinez","year":"2022","unstructured":"Martinez FJ, Wijsenbeek MS, Raghu G, Flaherty KR, Maher TM, Wuyts WA et al (2022) Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: a multicenter, randomized, placebo-controlled study (SCENIC Trial). Am J Respir Crit Care Med 205(9):1084\u201392","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"666_CR75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0304-3959(91)90100-C","volume":"44","author":"CJ Woolf","year":"1991","unstructured":"Woolf CJ, Thompson SWN (1991) The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 44(3):293\u20139","journal-title":"Pain."},{"issue":"4","key":"666_CR76","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1378\/chest.11-0554","volume":"141","author":"JA Smith","year":"2012","unstructured":"Smith JA, Hilton ECY, Saulsberry L, Canning BJ (2012) Antitussive effects of memantine in guinea pigs. Chest 141(4):996\u20131002","journal-title":"Chest"},{"key":"666_CR77","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00447-2021","author":"R Abdulqawi","year":"2021","unstructured":"Abdulqawi R, Satia I, Holt KJ, Dockry R, Sen S, Smith JA (2021) An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00447-2021","journal-title":"ERJ Open Res"},{"key":"666_CR78","unstructured":"Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection 2014. https:\/\/clinicaltrials.gov\/study\/NCT01597349."},{"key":"666_CR79","unstructured":"An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough 2014. https:\/\/clinicaltrials.gov\/study\/NCT01703923."},{"key":"666_CR80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00408-012-9370-3","volume":"190","author":"EC Young","year":"2012","unstructured":"Young EC, Pawsey S, Woodcock A, Smith JA (2012) An Open-label pilot study of V3381, a novel N methyl-D-aspartate receptor (NMDA-R) antagonist in chronic cough [abstract]. Lung. 190:63","journal-title":"Lung."},{"key":"666_CR81","unstructured":"Algernon pharmaceuticals: corporate fact sheet August 2023. https:\/\/d1io3yog0oux5.cloudfront.net\/_a79b357f6420bce4588b82609a1dca6e\/algernonpharmaceuticals\/db\/2291\/22410\/pdf\/Algernon+Pharma+August+24+2023.pdf."},{"issue":"4","key":"666_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/j.1552-4604.1998.tb04436.x","volume":"38","author":"PV Dicpinigaitis","year":"1998","unstructured":"Dicpinigaitis PV, Dobkin JB, Rauf K, Aldrich TK (1998) Inhibition of capsaicin-induced cough by the gamma-aminobutyric acid agonist baclofen. J Clin Pharmacol 38(4):364\u20137","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"666_CR83","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000029232","volume":"65","author":"PV Dicpinigaitis","year":"1998","unstructured":"Dicpinigaitis PV, Rauf K (1998) Treatment of chronic, refractory cough with baclofen. Respiration 65(1):86\u20138","journal-title":"Respiration"},{"key":"666_CR84","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.pupt.2021.102079","volume":"71","author":"H Badri","year":"2021","unstructured":"Badri H, LGibbard C, Denton D, Satia I, Dockry RJ, Holt K et al (2021) Effect of centrally and peripherally acting GABA(B) agonism on the healthy human cough reflex. Pulm Pharmacol Ther 71:102079","journal-title":"Pulm Pharmacol Ther"},{"key":"666_CR85","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00546-2021","author":"H Badri","year":"2022","unstructured":"Badri H, Gibbard C, Denton D, Satia I, Al-Sheklly B, Dockry RJ et al (2022) A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00546-2021","journal-title":"ERJ Open Res"},{"issue":"1","key":"666_CR86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","volume":"157","author":"J Smith","year":"2020","unstructured":"Smith J, Allman D, Badri H, Miller R, Morris J, Satia I et al (2020) The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest 157(1):111\u20138","journal-title":"Chest"},{"key":"666_CR87","unstructured":"(2021) Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough."},{"key":"666_CR88","first-page":"4564","volume":"56","author":"Y Kanemitsu","year":"2020","unstructured":"Kanemitsu Y, Smith JA, Butera P, Canning B, Dicpinigaitis P, Iyer V et al (2020) The efficacy of bradanicline in refractory chronic cough [abstract]. Eur Respir J 56:4564","journal-title":"Eur Respir J"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-023-00666-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T04:13:03Z","timestamp":1709007183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-023-00666-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s00408-023-00666-y","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAS has received consultancy fees from Axalbion, Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Nocion Therapeutics, Shionogi, and Trevi Therapeutics. The VitaloJAK algorithm has been licenced by Manchester University Foundation Trust (MFT) and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland. MFT receives royalties which may be shared with the clinical division in which JAS works.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}